In short
This article explores the use of Lithium Sulphate, Anhydrous in clinical trials, specifically focusing on its potential to prevent cognitive impairment in children who have undergone brain tumor radiotherapy. The LiBRA study aims to assess the efficacy of lithium treatment in preserving cognitive processing speed and other neuropsychological functions in young patients who have received cranial or craniospinal radiation treatment.
At a glance
- Study Name
- LiBRA – Lithium treatment to prevent cognitive impairment after brain radiotherapy
- Main Objective
- Assess efficacy of lithium in preventing cognitive processing speed impairment in children after CNS radiotherapy
- Participant Age Range
- 5 to 18 years at time of radiotherapy
- Treatment Duration
- Maximum 6 months
- Primary Endpoint
- Difference in Processing Speed Index (PSI) from baseline to two years later
- Secondary Endpoints
- Changes in neuropsychological test scores, quality of life measures, and brain MRI findings
- Drug Information
- Lithionit 42 mg (6 mmol) prolonged-release tablet, containing Lithium Sulphate, Anhydrous
- Administration Route
- Oral use
- Maximum Daily Dose
- 336 mg
What is Lithium Sulphate?
Lithium sulphate, anhydrous is a medication that is being studied for its potential to prevent cognitive impairment in children who have undergone brain tumor radiotherapy. It is also known by the brand name Lithionit and is classified as a type of medication called lithium.
Lithium is typically used to treat mood disorders, but researchers are now exploring its potential benefits for protecting the brain after radiation treatment. The medication comes in the form of a prolonged-release tablet, which means it releases the active ingredient slowly over time.
Purpose of the Study
The main goal of this study, called LiBRA (Lithium treatment to prevent cognitive impairment after brain radiotherapy), is to see if lithium treatment can help prevent cognitive problems in children who have received radiation therapy for brain tumors.
Specifically, the researchers want to find out if lithium can prevent a decrease in cognitive processing speed. This refers to how quickly a person can understand and react to information.
Who Can Participate?
The study is looking for participants who meet certain criteria:
- Children between 5 and 18 years old
- Have received radiation treatment for a brain tumor within the last 7 years
- Are able to use proper birth control methods during the study and for 6 months after
- Have permission from their parents or caregivers to participate
Some conditions that would prevent a child from participating include:
- Allergies to lithium
- Kidney problems
- Heart diseases
- Uncontrolled thyroid problems
- Pregnancy or breastfeeding
- Severe imbalances in body fluids or electrolytes
What the Study Involves
Participants in the study will receive lithium sulphate treatment. The medication is given as a tablet that slowly releases the drug over time. The maximum daily dose is 336 mg, and the treatment may last up to 6 months.
Throughout the study, researchers will conduct various tests to measure the effects of the treatment:
- Cognitive tests: These will assess things like processing speed, memory, and problem-solving skills.
- Quality of life questionnaires: To understand how the treatment affects overall well-being.
- Brain scans (MRI): To look at changes in brain structure and function.
These tests will be done before starting treatment and at various points during and after treatment, up to 5 years later.
Potential Benefits
If successful, this study could show that lithium treatment helps prevent cognitive problems in children who have had brain radiation. This could lead to improved quality of life and better long-term outcomes for these young patients.
Important Considerations
It's important to note that this is a research study, and the benefits of lithium for this purpose are not yet proven. Like all medications, lithium can have side effects and risks. The study team will closely monitor participants for any problems.
If you or your child are interested in participating in this study, it's crucial to discuss it thoroughly with your healthcare provider. They can help you understand the potential risks and benefits and determine if it might be appropriate for your situation.